T cell leukemia homeobox 1Genealiases: HOX11 · TCL3
Q-omics provides the consensus-scored TLX1 profile across patient tissues and cancer cell-line models. TLX1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TLX1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TLX1 RNA expression shows 12,185 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where TLX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLX1 survival associations across molecular data types. TLX1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLX1 RNA expression–survival associations across cancer types. High TLX1 expression shows unfavorable associations in KIRP, KIRC, ACC, UCEC and LUAD, but favorable associations in LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TLX1 RNA expression.
This table summarizes TLX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TLX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLX1 shows lower tumor expression in HNSC and higher tumor expression in COAD, STAD, LIHC, BRCA and LUSC. The COAD box plot shows higher TLX1 RNA expression in tumor versus normal tissue (log2 FC = +1.563, t-test p < 0.001).
This table shows molecular features associated with TLX1 in patient tissues and cancer cell lines. In patient samples, TLX1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TLX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
